News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe

News

Webcast

Webcasts

January 18, 2024

Navigating Success During a Rare Disease Product Launch

Author(s):

Herspiegel

Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST

Join us to learn about current trends in rare disease drug development and commercialization, as well as implications for rare disease product launches. In this webcast, we share learnings from our 125+ pharmaceutical product launches, insights to identify risk and strategies to mitigate them, and best practices for launch timelines and stage gates.

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Event Overview:

Rare disease products account for half of all US FDA approvals, most with fast-track designations, which means compressed launch timelines and increasingly competitive markets with smaller patient populations. Organizations need to start their project journey 24-36 months prior to approval to gain a comprehensive understanding of the patient journey, educate providers effectively, foster advocacy, and establish a clear path to diagnosis and access to treatment. Early alignment to a cross-functional strategy supports decisions about prioritizing and judiciously allocating limited resources pre-approval.

If you are developing assets for rare disease indications, take advantage of this presentation to learn how to ensure your launch is set up for success.

Key Learning Objectives:

  • Trends in rare disease drug development and commercialization
  • Unique considerations for major commercial decisions in rare disease markets
  • Identification of challenges and effective strategies to address them
  • Best practices for launch timelines and stage gates for Medical Affairs, Market Access, and Commercial perspectives

Who Should Attend:

  • CEOs, Chief Commercial Officers, Launch Leadership, Marketing Heads, EVPs of Marketing of organizations that are developing therapies for rare disease conditions.

Speakers:

Kapil Raina, MD
Principal, Market Access
Herspiegel

Brian Williams
SVP, Commercial Strategy and Execution
Herspiegel

Chris Zealey, MSc
Principal, Science and Strategy
Sixsense Strategy Group, a Herspiegel Company

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Lynlee Brown
Amy Hessels, Bayer
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content
Advertisement
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 1st 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 1st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma
August 1st 2025

Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma

Michael Christel
Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
2025 Pharm Exec Top 50 Companies
August 1st 2025

2025 Pharm Exec Top 50 Companies

Michael Christel
With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.
Innovation Requires Investment—and Sustained Investment Requires Sufficient Returns
August 1st 2025

Innovation Requires Investment—and Sustained Investment Requires Sufficient Returns

Barbara Ryan
Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.
Related Content
Advertisement
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 1st 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 1st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma
August 1st 2025

Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma

Michael Christel
Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
2025 Pharm Exec Top 50 Companies
August 1st 2025

2025 Pharm Exec Top 50 Companies

Michael Christel
With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.
Innovation Requires Investment—and Sustained Investment Requires Sufficient Returns
August 1st 2025

Innovation Requires Investment—and Sustained Investment Requires Sufficient Returns

Barbara Ryan
Special Guest Opinion: A reimagined regulatory framework for the life sciences is not just pro-investor—it is pro-patient.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.